Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Moat Biotechnology
AddedMar 20, 2024
UpdatedJun 18, 2026
Moat Biotechnology

Moat Biotechnology

Series A

Oklahoma City software firm & biopharmaceutical company developing innovative vaccines.

HQ
Oklahoma City, OK, US
Founded
2022
Overview
Compare
Fundraising
Employees

Based on the SC-AdVax platform that was exclusively licensed by the Mayo Clinic, Moat Biotechnology is a biopharmaceutical

firm in the clinical development stage that is dedicated to the development of innovative intranasal and oral vaccines.

Moat Biotechnology - Similar Companies

X-Vax Technology logo

X-Vax Technology

Aptimmune Biologics logo

Aptimmune Biologics

AmplifyBio logo

AmplifyBio

Omniose logo

Omniose

omniose.com

PaxVax logo

PaxVax

Sivec Biotechnologies logo

Sivec Biotechnologies

Bioscience Vaccines logo

Bioscience Vaccines

Uvax Bio logo

Uvax Bio

uvaxbio.com

InSitu Biologics logo

InSitu Biologics

Great Lakes Biologics logo

Great Lakes Biologics

Dynavax Technologies logo

Dynavax Technologies

dynavax.com

Pathovax logo

Pathovax

pathovax.com

Blue Lake Biotechnology logo

Blue Lake Biotechnology

Innovac Therapeutics logo

Innovac Therapeutics

innovactx.com

VitriVax logo

VitriVax

vitrivaxbio.com

Moat Biotechnology - Quick Facts

Who are Moat Biotechnology's competitors?

Companies similar to Moat Biotechnology include X-Vax Technology, Aptimmune Biologics, AmplifyBio and Omniose.

When was Moat Biotechnology founded?

Moat Biotechnology was founded in 2022.

Where is Moat Biotechnology's headquarters located?

Moat Biotechnology's headquarters is located in Oklahoma City, OK, US.

When was Moat Biotechnology's last funding round?

Moat Biotechnology's most recent funding round was for $6.5M (USD) in February 2023.

How much has Moat Biotechnology raised to-date?

As of Feb 9, 2023, Moat Biotechnology has raised a total of $8M (USD).

How many employees does Moat Biotechnology have?

Moat Biotechnology has 5 employees as of Feb 5, 2024.

Moat Biotechnology - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Vaccines
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software